[1] GAO B, JEONG W I, TIAN Z. Liver: An organ with predominant innate immunity[J]. Hepatology,2008,47(2):729-736.
[2] DOHERTY D G. Immunity, tolerance and autoimmunity in the liver: A comprehensive review[J]. J Autoimmun,2016,66:60-75. doi:  10.1016/j.jaut.2015.08.020
[3] GAO B. Cytokines, STATs and liver disease[J]. Cell Mol Immunol,2005,2(2):92-100.
[4] ZHAO J, QI Y F, YU Y R. STAT3: A key regulator in liver fibrosis[J]. Ann Hepatol,2021,21:100224. doi:  10.1016/j.aohep.2020.06.010
[5] CHUN J, PARK M K, KO H, et al. Bioassay-guided isolation of cantharidin from blister beetles and its anticancer activity through inhibition of epidermal growth factor receptor-mediated STAT3 and Akt pathways[J]. J Nat Med,2018,72(4):937-945. doi:  10.1007/s11418-018-1226-6
[6] ITSUJI T, TONOMURA H, ISHIBASHI H, et al. Hepatocyte growth factor regulates HIF-1α-induced nucleus pulposus cell proliferation through MAPK-, PI3K/Akt-, and STAT3-mediated signaling[J]. J Orthop Res,2021,39(6):1184-1191. doi:  10.1002/jor.24679
[7] KAWARATANI H, MORIYA K, NAMISAKI T, et al. Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review)[J]. Int J Mol Med,2017,40(2):263-270. doi:  10.3892/ijmm.2017.3015
[8] LIU J, YU Q, WU W, et al. TLR2 Stimulation Strengthens Intrahepatic Myeloid-Derived Cell-Mediated T Cell Tolerance through Inducing Kupffer Cell Expansion and IL-10 Production[J]. J Immunol,2018,200(7):2341-2351. doi:  10.4049/jimmunol.1700540
[9] ZHANG M, XU S, HAN Y, et al. Apoptotic cells attenuate fulminant hepatitis by priming Kupffer cells to produce interleukin-10 through membrane-bound TGF-β[J]. Hepatology,2011,53(1):306-316. doi:  10.1002/hep.24029
[10] KNOLLE P A, LöSER E, PROTZER U, et al. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10[J]. Clin Exp Immunol,1997,107(3):555-561.
[11] FRIEDMAN S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver[J]. Physiol Rev,2008,88(1):125-172. doi:  10.1152/physrev.00013.2007
[12] ZHANG W Q, GU G X, XIA Q. [Interactions between transforming growth factor beta and signal transducer and activator of transcription 3 in the development of liver fibrosis][J]. Zhonghua Gan Zang Bing Za Zhi,2018,26(10):792-796.
[13] IWAHASI S, RUI F, MORINE Y, et al. Hepatic Stellate Cells Contribute to the Tumor Malignancy of Hepatocellular Carcinoma Through the IL-6 Pathway[J]. Anticancer Res,2020,40(2):743-749. doi:  10.21873/anticanres.14005
[14] POISSON J, LEMOINNE S, BOULANGER C, et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases[J]. J Hepatol,2017,66(1):212-227. doi:  10.1016/j.jhep.2016.07.009
[15] LI Z, CHEN B, DONG W, et al. MKL1 promotes endothelial-to-mesenchymal transition and liver fibrosis by activating TWIST1 transcription[J]. Cell Death Dis,2019,10(12):899. doi:  10.1038/s41419-019-2101-4
[16] PARK O, WANG H, WENG H, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression[J]. Hepatology,2011,54(1):252-261. doi:  10.1002/hep.24339
[17] XIANG X, FENG D, HWANG S, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice[J]. J Hepatol,2020,72(4):736-745. doi:  10.1016/j.jhep.2019.11.013
[18] LAM S P, LUK J M, MAN K, et al. Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration[J]. Liver Transpl,2010,16(10):1195-1206. doi:  10.1002/lt.22136
[19] STREETZ K L, TACKE F, LEIFELD L, et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases[J]. Hepatology,2003,38(1):218-229. doi:  10.1053/jhep.2003.50268
[20] KROY D C, BERAZA N, TSCHAHARGANEH D F, et al. Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice[J]. Hepatology,2010,51(2):463-473. doi:  10.1002/hep.23322
[21] LIU E H, ZHENG Z N, XIAO C X, et al. IL-22 relieves sepsis-induced liver injury via activating JAK/STAT3 signaling pathway[J]. J Biol Regul Homeost Agents,2020,34(5):1719-1727.
[22] HORIGUCHI N, WANG L, MUKHOPADHYAY P, et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury[J]. Gastroenterology,2008,134(4):1148-1158. doi:  10.1053/j.gastro.2008.01.016
[23] SAKAMORI R, TAKEHARA T, OHNISHI C, et al. Signal transducer and activator of transcription 3 signaling within hepatocytes attenuates systemic inflammatory response and lethality in septic mice[J]. Hepatology,2007,46(5):1564-1573. doi:  10.1002/hep.21837
[24] MATSUKAWA A, TAKEDA K, KUDO S, et al. Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils[J]. J Immunol,2003,171(11):6198-6205. doi:  10.4049/jimmunol.171.11.6198
[25] LAFDIL F, WANG H, PARK O, et al. Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production[J]. Gastroenterology,2009,137(6):2125-2135.e1-2. doi:  10.1053/j.gastro.2009.08.004
[26] LI N, HUA J. Immune cells in liver regeneration[J]. Oncotarget,2017,8(2):3628-3639. doi:  10.18632/oncotarget.12275
[27] KHAN H A, AHMAD M Z, KHAN J A, et al. Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance[J]. Hepatobiliary Pancreat Dis Int,2017,16(3):245-256. doi:  10.1016/S1499-3872(17)60014-6
[28] YIN S, WANG H, PARK O, et al. Enhanced liver regeneration in IL-10-deficient mice after partial hepatectomy via stimulating inflammatory response and activating hepatocyte STAT3[J]. Am J Pathol,2011,178(4):1614-1621. doi:  10.1016/j.ajpath.2011.01.001
[29] YAMADA Y, KIRILLOVA I, PESCHON J J, et al. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor[J]. Proc Natl Acad Sci U S A,1997,94(4):1441-1446. doi:  10.1073/pnas.94.4.1441
[30] CRESSMAN D E, GREENBAUM L E, DEANGELIS R A, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice[J]. Science,1996,274(5291):1379-1383. doi:  10.1126/science.274.5291.1379
[31] ZHANG Y M, LIU Z R, CUI Z L, et al. Interleukin-22 contributes to liver regeneration in mice with concanavalin A-induced hepatitis after hepatectomy[J]. World J Gastroenterol,2016,22(6):2081-2091. doi:  10.3748/wjg.v22.i6.2081
[32] BATALLER R, BRENNER D A. Liver fibrosis[J]. J Clin Invest,2005,115(2):209-218. doi:  10.1172/JCI24282
[33] AYDıN M M, AKçALı K C. Liver fibrosis[J]. Turk J Gastroenterol,2018,29(1):14-21. doi:  10.5152/tjg.2018.17330
[34] FRIEDMAN S L. Mechanisms of hepatic fibrogenesis[J]. Gastroenterology,2008,134(6):1655-1669. doi:  10.1053/j.gastro.2008.03.003
[35] KOVALOVICH K, DEANGELIS R A, LI W, et al. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice[J]. Hepatology,2000,31(1):149-159. doi:  10.1002/hep.510310123
[36] HOU X, YIN S, REN R, et al. Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis[J]. Hepatology,2021,74(1):116-132. doi:  10.1002/hep.31658
[37] MAIR M, ZOLLNER G, SCHNELLER D, et al. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis[J]. Gastroenterology,2010,138(7):2499-2508. doi:  10.1053/j.gastro.2010.02.049
[38] LI H G, YOU P T, XIA Y, et al. Yu Gan Long Ameliorates Hepatic Fibrosis by Inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 Signaling Pathways in CCl4-induced Liver Fibrosis Rats[J]. Curr Med Sci,2020,40(3):539-547. doi:  10.1007/s11596-020-2211-3
[39] SU T H, SHIAU C W, JAO P, et al. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition[J]. Proc Natl Acad Sci U S A,2015,112(23):7243-7248. doi:  10.1073/pnas.1507499112
[40] ZIMMERS T A, FISHEL M L, BONETTO A. STAT3 in the systemic inflammation of cancer cachexia[J]. Semin Cell Dev Biol,2016,54:28-41. doi:  10.1016/j.semcdb.2016.02.009
[41] WANG Y, SHEN Y, WANG S, et al. The role of STAT3 in leading the crosstalk between human cancers and the immune system[J]. Cancer Lett,2018,415:117-128. doi:  10.1016/j.canlet.2017.12.003
[42] VILLANUEVA A. Hepatocellular Carcinoma[J]. N Engl J Med,2019,380(15):1450-1462. doi:  10.1056/NEJMra1713263
[43] YANG J D, HAINAUT P, GORES G J, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol,2019,16(10):589-604. doi:  10.1038/s41575-019-0186-y
[44] ABIRU S, MIGITA K, MAEDA Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis[J]. Liver Int,2006,26(1):39-45. doi:  10.1111/j.1478-3231.2005.01191.x
[45] NAUGLER W E, SAKURAI T, KIM S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production[J]. Science,2007,317(5834):121-124. doi:  10.1126/science.1140485
[46] ZUO M, LI C, LIN J, et al. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy[J]. Oncotarget,2015,6(13):10940-10949. doi:  10.18632/oncotarget.3458
[47] WANG B, LIU T, WU J C, et al. STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration[J]. Biomed Pharmacother,2018,98:214-221. doi:  10.1016/j.biopha.2017.12.035
[48] YANG S F, WANG S N, WU C F, et al. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma[J]. J Clin Pathol,2007,60(6):642-648. doi:  10.1136/jcp.2006.036970
[49] JIANG L H, HAO Y L, ZHU J W. Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol,2019,43(3):282-291. doi:  10.1016/j.clinre.2018.09.011
[50] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet,2018,391(10127):1301-1314. doi:  10.1016/S0140-6736(18)30010-2
[51] KUDO M, FINN R S, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173. doi:  10.1016/S0140-6736(18)30207-1
[52] JUNG K H, YOO W, STEVENSON H L, et al. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice[J]. Clin Cancer Res,2017,23(18):5537-5546. doi:  10.1158/1078-0432.CCR-16-2253